Study #2024-1144
The use of cytomegalovirus cell mediated immunity to optimize the duration of letermovir prophylaxis in hematopoietic cell transplant recipients
MD Anderson Study Status
Enrolling
Treatment Agent
Description
The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking letermovir every day without interruption.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cytomegalovirus Cell Mediated Immunity;Hematopoietic Cell Transplant
Study phase:
Physician name:
Fareed Khawaja
Department:
Infectious Diseases
For general questions about clinical trials:
1-844-939-2381
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.